USAID Cuts Block HIV Prevention Drug Access in Africa

Empty Shelves in South Africa's Clinics

In the bustling townships of South Africa, the abstract concept of aid cuts translates into a visceral, daily struggle for survival.

Vulnerable South Africans are already struggling to find HIV medication after the U.S. foreign aid reductions took effect earlier this year.

Reports from August 2025 detailed scenes of despair in clinics that once served as lifelines.

Patients who travelled miles for their monthly antiretroviral therapy were told the stocks were depleted.

The disruption in supply chains has created a vacuum that opportunistic infections are quick to fill.

South Africa carries the world's largest HIV burden, with approximately 8.2 million people living with the virus.

The U.S. President's Emergency Plan for AIDS Relief (PEPFAR), largely administered through USAID, has historically supported a significant portion of this population's treatment.

When that funding spigot tightens, the ripples are felt immediately.

• Clinics in rural provinces have reported stockouts lasting weeks.
• Patients are forced to share medication or interrupt treatment, risking drug resistance.
• Community health workers have been laid off due to budget shortfalls.

The human cost of these policy decisions is visible on the ground.

A mother unable to access prevention medication faces a terrifying calculus regarding her child's future.

A young man who relies on PrEP to stay negative finds himself suddenly exposed.

These are not statistics; they are neighbours, friends, and family members.

The cuts have dismantled trust in the health system.

It takes years to build a reliable patient network and only weeks to destroy it.

Witnesses reported that confusion reigns in many health centres, as staff are often unaware of when the next shipment might arrive.

This uncertainty drives patients away from formal healthcare entirely.

Once lost to follow-up, these individuals become invisible to the system but remain active vectors for transmission.

The collapse of adherence is the first step toward a resurgence of the epidemic.

Experts noted that the psychological toll of being told a life-saving drug is unavailable cannot be underestimated.

It breeds cynicism and fatalism, which are potent enemies of public health campaigns.

9 Million Children at Risk from TB Surge

The repercussions of U.S. funding cuts extend far beyond HIV, threatening to unleash a secondary catastrophe of tuberculosis among children.

Harvard T.H. Chan School of Public Health researchers released alarming projections in October 2025, quantifying the lethal fallout of reduced aid.

Their analysis suggests that the withdrawal of U.S. support for HIV programmes will indirectly result in nearly 9 million additional child tuberculosis cases.

Furthermore, the models predict a staggering 1.5 million child deaths attributable to this funding gap.

The link between HIV and TB is biological and unbreakable.

HIV compromises the immune system, making people living with the virus exponentially more susceptible to contracting active tuberculosis.

When HIV treatment and prevention programmes falter, TB rates inevitably spike.

Children are particularly vulnerable in this scenario.

They often contract TB from undiagnosed, untreated adults in their households.

• HIV is the strongest known risk factor for developing TB disease.
• The Harvard study covered projections over a four-year period following the aid cuts.
• TB is among the leading causes of death for children living with HIV globally.

The mechanics of this surge are grim.

As HIV-positive adults lose access to antiretrovirals due to the USAID cuts, their viral loads increase, weakening their immune systems.

Latent TB awakens.

They become infectious.

In cramped, poorly ventilated homes, the bacteria spread to children.

Without the robust screening and preventive therapy that U.S. funds previously supported, these children progress from infection to active disease rapidly.

The 9 million cases figure is not an abstract probability; it is a mathematical projection based on the dismantling of integrated health services.

Officials said that the decision to cut HIV funding is, in effect, a decision to allow TB to spread unchecked.

Treating drug-resistant TB is exponentially more expensive than preventing HIV or treating standard TB.

Therefore, the austerity measures are a false economy.

The Harvard report serves as a dire warning to policymakers: you cannot cut one thread of the healthcare tapestry without unravelling the rest.

The focus on HIV prevention drugs is crucial, but it cannot be isolated from the broader ecosystem of infectious disease control.

When the safety net breaks, the most vulnerable fall through first—and in this case, the victims are millions of children.

Why the New Prevention Drug Matters

At the centre of this controversy is a specific medical advancement that represents a paradigm shift in how we approach HIV prevention.

The drug in question is a long-acting formulation of cabotegravir, sold under the brand name Apretude.

Unlike daily oral pills, which require strict adherence, this injection provides protection against HIV for two months with a single shot.

For populations where daily pill-taking is stigmatized, logistically difficult, or simply forgotten, this injection is a game-changer.

Clinical trials have shown it to be significantly more effective than daily oral PrEP at preventing infection in cisgender women and men who have sex with men.

The science is robust.

The drug works by interfering with the virus's ability to integrate its genetic material into human cells.

By blocking integrase, an enzyme HIV needs to replicate, the virus remains unable to establish a permanent infection.

• The injection is administered once every two months.
• Studies showed it was 66% more effective than daily pills in one key trial.
• The high cost of the drug has previously been a barrier to rollout in Africa.

The introduction of this technology was supposed to mark the beginning of the end for new HIV infections.

Public health experts designed ambitious rollout plans targeting high-incidence regions in sub-Saharan Africa.

However, these plans relied heavily on donor funding to subsidize the high initial cost of the drug and the logistics of cold-chain storage.

The USAID cuts have severed this lifeline.

Without the purchasing power of the U.S. government, which often negotiates lower prices for low-income countries, the drug remains prohibitively expensive for most health ministries.

Experts pointed out that this creates a cruel paradox.

The global north has the science, and the global south has the need, but the financial bridge has been burned.

The failure to deploy this drug effectively squanders years of research and investment.

It also sends a demoralizing message to communities that have been promised better tools.

Prevention is always cheaper than treatment.

A lifetime of HIV antiretroviral therapy costs far more than a course of prevention injections.

By refusing to fund the prevention drug now, donors are guaranteeing a much larger financial burden in the future as those who would have been protected become infected and require lifelong care.

The logic of the cuts, from a purely fiscal standpoint, is fundamentally flawed.

Sub-Saharan Africa Faces a Global Risk

The instability caused by these reductions is not confined within the borders of the nations most affected.

In January 2026, infectious disease experts warned that U.S. cuts to HIV programmes in sub-Saharan Africa pose a direct global risk.

The reasoning is rooted in the mobility of viruses and the interconnectedness of modern travel.

When HIV prevalence is allowed to surge in one region due to collapsed treatment programmes, it increases the statistical probability of new, potentially drug-resistant strains emerging.

Viruses mutate when they replicate unchecked in a population with suboptimal treatment coverage.

If patients are forced to skip doses due to stockouts caused by funding cuts, the virus learns to survive the medication.

These resistant strains can then travel.

• Sub-Saharan Africa accounts for over two-thirds of the global HIV population.
• Air travel connects major African hubs to London, New York, and Paris within hours.
• Drug-resistant HIV is significantly harder and more expensive to treat.

The concept of